Over 12 months, Salarius Pharmaceuticals, Inc. saw more buying than selling from its insiders — purchases of about $20,000 against sales of $17.
Rosenblum Mark J (CFO) made the biggest buy, worth around $16,000. Notably, at least one C-suite executive was among the buyers.
Zooming out by quarter: No open-market insider buying or selling in the last full quarter. Insiders bought in 1 of the last 7 full quarters.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Jan 2, 2026 | HANISH ARNOLD C | Director | Sell | 15 | $0.64 | $10 | SEC |
| Jan 2, 2026 | HANISH ARNOLD C | Director | Sell | 12 | $0.64 | $8 | SEC |
| Nov 24, 2025 | HANISH ARNOLD C | Director | Buy | 5,000 | $0.75 | $4K | SEC |
| Nov 20, 2025 | Rosenblum Mark J | CFO | Buy | 20,000 | $0.80 | $16K | SEC |
In the last 12 months Salarius Pharmaceuticals, Inc. insiders made open-market purchases worth about $20,000 and sales worth about $17. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in SLRX was filed on 2026-01-02.
No congressional trades in SLRX were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).